Repare Therapeutics (NASDAQ:RPTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Repare Therapeutics (NASDAQ:RPTX) to a hold rating in a research report sent to investors on Saturday morning.

Several other research firms also recently weighed in on RPTX. HC Wainwright decreased their target price on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Repare Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.50.

Repare Therapeutics Price Performance

Repare Therapeutics stock traded down $0.04 during midday trading on Friday, reaching $1.65. The company had a trading volume of 2,285,416 shares, compared to its average volume of 186,292. Repare Therapeutics has a 12-month low of $0.89 and a 12-month high of $4.07. The company has a market capitalization of $70.88 million, a P/E ratio of -0.98 and a beta of 1.06. The firm’s fifty day simple moving average is $1.78 and its 200-day simple moving average is $1.58.

Institutional Investors Weigh In On Repare Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quinn Opportunity Partners LLC purchased a new position in shares of Repare Therapeutics during the 2nd quarter worth approximately $56,000. XTX Topco Ltd acquired a new position in Repare Therapeutics during the second quarter worth $60,000. Squarepoint Ops LLC purchased a new position in shares of Repare Therapeutics during the third quarter worth $115,000. Affinity Asset Advisors LLC grew its stake in shares of Repare Therapeutics by 100.0% in the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock valued at $197,000 after buying an additional 100,000 shares in the last quarter. Finally, Militia Capital Partners LP acquired a new position in Repare Therapeutics during the 2nd quarter worth about $166,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.